Recipe - Compounding Worksheet
Unauthorized distribution, copying or disclosure prohibited.
These recipes are intended for use by the pharmacy manufacturing departments only.
Famotidine Oral Suspension   8 mg/mL
Lot No Expiry(mm/yyyy) Ingredients Master Formula
    famotidine  40 mg  TAB   
    Water, sterile        
    Ora-Plus® / Ora-Sweet®  1:1  SYRUP  qs to 
Recipe Total Quantity:
Final Quantity Desired: mL

Directions: 1. In a mortar, crush tablets and triturate to a fine powder.
2. Gradually levigate powder with sterile water to form a paste.
3. Mix Ora-Plus® and Ora-Sweet® together (1:1) to make vehicle.
4. Levigate vehicle with paste until a liquid is formed.
5. Pour into a graduated cylinder.
6. Rinse mortar and qs to final volume with vehicle.
7. Transfer to final container and label.

Notes Famotidine tablets are Non-Formulary with a Therapeutic Interchange.
Refer to Famotidine tablets in AHS Provincial Formulary.

Ora-Blend® can be used instead of Ora-Plus® /Ora-Sweet® (1:1).

Cherry Syrup may also be used, but formulation is only stable for 20 days refrigerated or 15 days at room temperature.
If cherry syrup is used, please note recipe requires the ready-to-use cherry syrup and NOT the cherry syrup concentrate. If your site uses the concentrate, it MUST be diluted before using in the recipe.

Store in an amber glass or polyethylene bottle.

Store at room temperature if Oral-Sweet/Ora-Plus or Ora-Blend vehicles are used
May store at room temperature or refrigerate if Cherry Syrup vehicle is used
Label with appropriate auxiliary label for storage given vehicle used

Packaging:  Amber Glass Bottle

Auxiliary Labels: Shake Well
  Store as indicated by auxiliary labels

Storage/Expiry:Refrigerator: 20 days (with Cherry Syrup)
  Room Temperature: 95 days (with Ora-Blend® or Ora-Plus®/ Ora-Sweet® 1:1)
  Room Temperature: 15 days (with Cherry Syrup)

Last Date Revised: 30-Sep-19

References:Dentinger PJ. Swenson CF. Anaizi NH. Stability of famotidine in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm 2000: 57:1340-1342.

Quercia RA. Jay GT. Fan C. Chow MS. Stability of famotidine in an extemporaneously oral liquid. Am J Health-Systm Pharm 1993; 50:691-693.
 
Nahata MC, Pai VB, Hipple TF. Pediatric drug formulations. 5th ed. Cincinnati, OH: Harvey Whitney Books Company; 2003.

Completed Compound Check
Lot NoDate Prepared Expiry DateTechnicianPharmacist
   6-Dec-2021         


This content is provided for general information purposes only. It is not intended to replace consultations with a health care professional or to provide medical advice, diagnosis or treatment. Always seek the advice of a physician or other qualified health care provider with any medical or health questions. Alberta Health Services accepts no responsibility for any modification or redistribution of this document and is not liable for any actions taken by individuals based on the information provided, or for any inaccuracies, errors, or omissions in the information in this document. These recipes are to be used as a reference and are not intended to be master formulation records. Not all recipes may be compliant with NAPRA or other standards.